Your browser doesn't support javascript.
loading
Population pharmacokinetics of buprenorphine and naloxone sublingual combination in Chinese healthy volunteers and patients with opioid use disorder: Model-based dose optimization.
Gu, Meng; Li, Anning; Mak, Wenyao; Dong, Fang; Xu, Nuo; Zhang, Jingye; Shi, Yufei; Zheng, Nan; Tang, Zhijia; He, Qingfeng; Ruan, Canjun; Guo, Wei; Xiang, Xiaoqiang; Wang, Chuanyue; Han, Bing; Zhu, Xiao.
Afiliación
  • Gu M; Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, China.
  • Li A; Department of Pharmacy, Minhang Hospital, Fudan University, Shanghai, China.
  • Mak W; The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China.
  • Dong F; Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China.
  • Xu N; Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, China.
  • Zhang J; The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China.
  • Shi Y; Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China.
  • Zheng N; Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, China.
  • Tang Z; Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, China.
  • He Q; Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, China.
  • Ruan C; The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China.
  • Guo W; Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China.
  • Xiang X; Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, China.
  • Wang C; Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, China.
  • Han B; The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China.
  • Zhu X; Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China.
Front Pharmacol ; 14: 1089862, 2023.
Article en En | MEDLINE | ID: mdl-36744255
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Pharmacol Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Pharmacol Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza